Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.59 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3342502 | 0.85 | BCL2L1 (0.59) | BCL2L1GPR35CHRNA7TBXAS1MEN1 | |
| SCHEMBL999671 | 0.83 | HDAC1 (0.56) | BCL2L1CA2CHRNA7HTR3AMEN1 | |
| SCHEMBL7785404 | 0.82 | BCL2L1 (0.83) | BCL2L1GPR35CA2HDAC1HDAC3 | |
| SCHEMBL5525703 | 0.82 | HDAC1 (0.66) | CHRNA7HTR3AHDAC1HDAC3HDAC4 | |
| SCHEMBL8250577 | 0.79 | BCL2L1 (0.61) | BCL2L1GPR35CA2TBXAS1MAPT | |
| SCHEMBL15697571 | 0.79 | GPR35 (0.61) | BCL2L1GPR35CA2TBXAS1HDAC1 | |
| SCHEMBL13709631 | 0.78 | F9 (0.49) | CA2CHRNA7HTR3AMAPTHDAC6 | |
| SCHEMBL156320 | 0.78 | BCL2L1 (0.59) | BCL2L1GPR35CHRNA7TBXAS1MCL1 | |
| SCHEMBL20614435 | 0.78 | BCL2L1 (0.59) | BCL2L1GPR35TBXAS1HDAC1HDAC3 | |
| SCHEMBL20614582 | 0.78 | BCL2L1 (0.59) | BCL2L1GPR35TBXAS1HDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109574986-B | 6-aminobenzo [ b ] thiophene-2-carboxylic acid derivative and application thereof in anti-epilepsy aspect | 聊城大学 | 2020-10-27 | — | — | CN | claimed |
| JP-4511835-B2 | — | — | 2010-07-28 | — | — | JP | claimed |
| US-7273856-B2 | Linear basic compounds having NK-2 antagonist activity and formulations thereof | MENARINI RICERCHE S.P.A. (IT) | 2007-09-25 | — | — | US | claimed |
| EP-1442050-B1 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI SAS (IT) | 2006-09-13 | — | — | EP | claimed |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2004-12-23 | — | — | US | claimed |
| EP-1442050-A2 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI ISTITUTO FARMACOBIOLOGICO S.p.A. (IT) | 2004-08-04 | — | — | EP | claimed |
| WO-2003037916-A2 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2003-05-08 | — | — | WO | claimed |
| CN-109574986-B | 6-aminobenzo [ b ] thiophene-2-carboxylic acid derivative and application thereof in anti-epilepsy aspect | 聊城大学 | 2020-10-27 | — | — | CN | disclosed |
| CN-109574986-B | 6-aminobenzo [ b ] thiophene-2-carboxylic acid derivative and application thereof in anti-epilepsy aspect | 聊城大学 | 2020-10-27 | — | — | CN | disclosed |
| CN-109574986-B | 6-aminobenzo [ b ] thiophene-2-carboxylic acid derivative and application thereof in anti-epilepsy aspect | 聊城大学 | 2020-10-27 | — | — | CN | disclosed |
| US-10196388-B2 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-02-05 | — | — | US | disclosed |
| US-20180127409-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-10 | — | — | US | disclosed |
| US-9955689-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-01 | — | — | US | disclosed |
| EP-1677731-A2 | THIOPHENE AND BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES | Aton Pharma, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20060106096-A1 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | BAYER HEALTH AG (DE) | 2006-05-18 | — | — | US | disclosed |
| US-20050119325-A1 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | FMR LLC | 2005-06-02 | — | — | US | disclosed |
| WO-2005034880-A2 | THIOPHENE AND BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES | ATON PHARMA, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2004-12-23 | — | — | US | disclosed |
| EP-1442050-A2 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI ISTITUTO FARMACOBIOLOGICO S.p.A. (IT) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003037916-A2 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127409-A1 | AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA5, CHRNA4 | BCL2L1 2385/4885GPR35 141/4885CA2 1496/4885 |
| US-20060106096-A1 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | CHRNA7, CHRNA5, CHRNA4 | BCL2L1 2402/4885GPR35 146/4885CA2 1306/4885 |
| US-20050119325-A1 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | CHRNA2, CHRNA7, CHRNA3 | BCL2L1 3373/4885GPR35 276/4885CA2 1602/4885 |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | BDKRB2, BDKRB1, TACR2 | BCL2L1 2632/4885GPR35 674/4885CA2 471/4885 |
| US-10196388-B2 | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | CHRNA7, CHRNA5, CHRNA4 | BCL2L1 2385/4885GPR35 141/4885CA2 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.